CGNSF (Cognetivity Neurosciences) ROCE % : 0.00% (As of Oct. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cognetivity Neurosciences's annualized ROCE % for the quarter that ended in Oct. 2023 was 0.00%.

Cognetivity Neurosciences ROCE % Historical Data

The historical data trend for Cognetivity Neurosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences ROCE % Chart

Cognetivity Neurosciences Annual Data

Trend

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

ROCE %

Get a 7-Day Free Trial

-205.31

-2,501.89

-612.55

Cognetivity Neurosciences Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
ROCE %	Get a 7-Day Free Trial															-2,030.65	-	-	-	-

Cognetivity Neurosciences ROCE % Calculation

Cognetivity Neurosciences's annualized ROCE % for the fiscal year that ended in Jan. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jan. 2023 )		(A: Jan. 2022 )		(A: Jan. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jan. 2023 )		(A: Jan. 2022 )		(A: Jan. 2023 )
	=	-4.773	/	( ( (1.588 - 4.401)	+	(2.108 - 7.893) )	/ 2 )
	=	-4.773	/	( (-2.813	+	-5.785)	/ 2 )
	=	-4.773	/	-4.299
	=	111.03 %

Cognetivity Neurosciences's ROCE % of for the quarter that ended in Oct. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2023 )		(Q: Jul. 2023 )		(Q: Oct. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2023 )		(Q: Jul. 2023 )		(Q: Oct. 2023 )
	=	-2.064	/	( ( (0.416 - 10.506)	+	(0.355 - 11.437) )	/ 2 )
	=	-2.064	/	( ( -10.09	+	-11.082 )	/ 2 )
	=	-2.064	/	-10.586
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Oct. 2023) EBIT data.

Cognetivity Neurosciences (OTCPK:CGNSF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cognetivity Neurosciences ROCE % Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cognetivity Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (OTCPK:CGNSF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

1UB:Germany CGN:Canada

Address

800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6

Website

https://www.cognetivity.com

Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences Headlines

From GuruFocus

The Most Innovative Healthcare AI Developments of 2019

By ACCESSWIRE AccessWire • 04-12-2019

Three Companies Using AI and Innovation to Lead Healthcare Sector

By ACCESSWIRE AccessWire • 04-12-2019